CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 55 enrolled
Drug / intervention
Conformable GORE® TAG® Thoracic Endoprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05414318
NCT05414318N/ACompleted
CompareCT.gov

Post Marketing Surveillance of the Conformable GORE® TAG® Thoracic Endoprosthesis (CTAG)

W.L.Gore & Associates·observational·Posted Jun 10, 2022·Updated Oct 3, 2024

In Brief

An observational study evaluating Conformable GORE® TAG® Thoracic Endoprosthesis for Thoracic Aortic Aneurysm and 2 related conditions. Completed, enrolled 55 participants.

Detailed Summary

Post Marketing Surveillance of the Conformable GORE® TAG® Thoracic Endoprosthesis

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsThoracic Aortic Aneurysm, Thoracic Aorta Injury, Thoracic Aortic Dissection
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 10, 2022
Enrollment StartJan 5, 2016
Primary CompletionDec 23, 2022
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 4.1 years ago

Interventions

Conformable GORE® TAG® Thoracic Endoprosthesisdevice

Thoracic Endoprosthesis